Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H3

B7-H3

Brief Information

Name:CD276 antigen
Target Synonym:B7 homolog 3,PSEC0249,UNQ309/PRO352,B7-H3,CD276 antigen,B7H3,CD276,CD276 Molecule,Costimulatory Molecule,4Ig-B7-H3,B7RP-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Phase 3 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BDA202203 B7H3+ and PD-L1+/low cancer CMC development License-out or co-development

Product ListCompare or Buy

Part of Bioactivity data

B73-H52E2-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).

B73-C52Ha-ELISA
Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

B73-C52Ha-MALS-HPLC
Cynomolgus B7-H3, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) is more than 90% and the molecular weight of this protein is around 65-85 kDa verified by SEC-MALS.

Bioactivity-ELISA
Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Synonym Name

B7-H3,CD276,B7 homolog 3

Background

B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Monoclonal antibody 8H9 I-124 124I-8H9; 124I-8H9-(B7-H3) Phase 2 Clinical Memorial Sloan Kettering Cancer Center Glioma Details
SCRI-CARB7H3 SCRI-CARB7H3 Phase 1 Clinical Seattle Children'S Hospital Central Nervous System Neoplasms; Glioma Details
4SCAR-276 4SCAR-276 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy CD276 CAR-T Phase 2 Clinical Shenzhen University General Hospital Pancreatic Neoplasms Details
Enoblituzumab MGA-271; TJ271 Phase 2 Clinical Macrogenics Head and Neck Neoplasms; Rhabdomyosarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Desmoplastic Small Round Cell Tumor; Carcinoma, Renal Cell; Wilms Tumor; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MGC-018 MGC-018 Phase 2 Clinical Macrogenics Neoplasms Details
Monoclonal antibody 8H9 I-131 8H9-MAb; 131-I-8H9; 131I-8H9-(B7-H3) Phase 3 Clinical Memorial Sloan Kettering Cancer Center Neuroblastoma; Peritoneal Neoplasms; Central Nervous System Diseases; Neoplasm Metastasis Details
B7-H3 CAR-T cell therapy (Zhejiang University) Phase 2 Clinical Zhejiang University Alumni Association (Singapore) Glioblastoma Details
Obrindatamab MGD-009; B7-H3 x CD3 Phase 2 Clinical Macrogenics Sarcoma, Synovial; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Neuroblastoma; Neurofibrosarcoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma Details
DS-7300 DS-7300 Phase 2 Clinical Daiichi Sankyo Co Ltd Solid tumours Details
Anti-CD276 CAR T-cell therapy (Persongen ) Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms Details
Mirzotamab clezutoclax ABBV-155 Phase 1 Clinical Abbvie Inc Hematologic Neoplasms; Solid tumours Details
Fully Human B7H3 CAR-T Cells Therapy fhB7H3.CAR-Ts Phase 2 Clinical The Affiliated Hospital Of Xuzhou Medical University Ovarian Neoplasms Details
Omburtamab I-131 Phase 1 Clinical Y-Mabs Central Nervous System Neoplasms; Sarcoma; Neuroblastoma; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma Details
177Lu-DTPA-omburtamab Phase 2 Clinical Y-Mabs Solid tumours; Meningeal Neoplasms Details
B7-H3-targeting CAR-T cell therapy (Beijing Tiantan Hospital, Capital Medical University) Beijing Tiantan Hospital, Capital Medical University Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message